About ERLEADA®

ERLEADA® is an androgen receptor (AR) inhibitor indicated to treat mCSPC and non-metastatic CRPC1

CRPC = castration-resistant prostate cancer; mCSPC = metastatic castration-sensitive prostate cancer; nmCRPC = non-metastatic castration-resistant prostate cancer.

Reference

1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.